

- tease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. *Leukemia* 2000;14:1276-83.
21. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. *J. Urol.* 1984;132:61-3.
22. Tewari M, Quan LT, O'Rourke K, et al. Yama/ CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell* 1995;81:801-9.
23. Dismukes WE, Stamm AM, Graybill JR, et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. *Ann. Intern. Med.* 1983;98:13-20.
24. Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. *Pharmacotherapy* 1984;4:343-73.
25. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. *Clin. Pharmacokin.* 1988; 14:13-34.
26. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res.* 1994;54:4855-78.
27. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. *Curr. Opin Genet Develop.* 1996;6: 12-8.
28. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. *Cancer Res.* 1994;54:1169-74.
29. Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. *J. Urol.* 1989;141:190-1.
30. Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. *Jpn. J. Cancer Res.* 2000;91:416-23.
31. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. *J. Clin. Oncol.* 2000;18:1465-73.
32. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. *J. Clin. Oncol.* 2000;18: 385-94.
33. Weller M. Predicting response to cancer chemotherapy: the role of p53. *Cell Tissue Res.* 1998;292:435-45.
34. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. *Oncology* 2000;58:52-9.
35. Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. *J. Biol. Chem.* 1995; 270:26049-52.
36. Ho YS, Liu HL, Duh JS, et al. Induction of apoptosis by S-nitrosoglutathione and Cu²⁺ or Ni²⁺ ion through modulation of bax, bad, and bcl-2 proteins in human colon adenocarcinoma cells. *Mol. Carcinogen.* 1999;26: 201-11.
37. Ho YS, Wang YJ, Lin JK. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. *Mol. Carcinogen.* 1996;16:20-31.
38. Ho YS, Lee HM, Mou TC, Wang YJ, Lin JK. Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. *Mol. Carcinogen.* 1997;19:101-13.
39. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC. Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. *Oncogene* 1996;12: 187-92.